Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder

Expert Review of Neurotherapeutics

Volumn 13, Issue 7, 2013, Pages 827-842

  Pfaffenseller, Bianca ^a,b   Fries, Gabriel R ^a,b   Wollenhaupt Aguiar, Bianca ^a,b   Colpo, Gabriela D ^a,b   Stertz, Laura ^a,b   Panizzutti, Bruna ^a,b   Magalhães, Pedro Vs ^a,b   Kapczinski, Flávio ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Bipolar disorder; Endoplasmic reticulum stress; Glial dysfunction; Illness activity; Inflammation; Mitochondrial dysfunction; neurotrophins; Novel therapies; Oxidative stress; Peripheral biomarkers; Systemic toxicity

Indexed keywords

ACETYLCYSTEINE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LITHIUM; MINOCYCLINE; MOOD STABILIZER; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; OMEGA 3 FATTY ACID; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

BIPOLAR DEPRESSION; BLOOD BRAIN BARRIER; CHRONIC STRESS; COGNITIVE DEFECT; DISEASE MARKER; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GLIA CELL; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; NERVE CELL PLASTICITY; NEUROTOXICITY; OXIDATIVE STRESS; PROTEIN TRANSPORT; REVIEW; SUPPLEMENTATION;

BIOLOGICAL MARKERS; BIPOLAR DISORDER; COMORBIDITY; HUMANS; INFLAMMATION; NERVE GROWTH FACTORS; NEUROGLIA; OXIDATIVE STRESS;

EID: 84883173403     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.811981     Document Type: Review

References (168)

1. Soreca I, Frank E, Kupfer DJ. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis? Depress. Anxiety 26(1), 73-82 (2009).
2. Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychother. Psychosom. 78(5), 285-297 (2009).
3. Magalhães PV, Kapczinski F, Nierenberg AA et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr. Scand. 125(4), 303-308 (2012).
4. Wingo AP, Harvey PD, Baldessarini RJ. Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord. 11(2), 113-125 (2009).
5. Rosa AR, González-Ortega I, González- Pinto A et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr. Scand. 125(4), 335-341 (2012).
6. Berk M, Hallam K, Malhi GS et al. Evidence and implications for early intervention in bipolar disorder. J. Ment. Health 19(2), 113-126 (2010).
7. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann. Clin. Psychiatry 20(3), 131-137 (2008).
8. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32(4), 675-692 (2008).
9. Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol. Behav. 106(1), 46-50 (2012).
10. Vieta E, Popovic D, Rosa AR et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur. Psychiatry 28(1), 21-29 (2013).
11. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm. Behav. 43(1), 2-15 (2003).
12. McEwen BS, Gianaros PJ. Stress- and allostasis-induced brain plasticity. Annu. Rev. Med. 62, 431-445 (2011).
13. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35(3), 804-817 (2011).
14. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res. 45(2), 156-161 (2011).
15. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol. Psychiatry 15(8), 784-786 (2010).
16. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci. Biobehav. Rev. 35(1), 2-16 (2010).
17. Fries GR, Pfaffenseller B, Stertz L et al. Staging and neuroprogression in bipolar disorder. Curr. Psychiatry Rep. 14(6), 667-675 (2012).
18. Singh I, Rose N. Biomarkers in psychiatry. Nature 460(7252), 202-207 (2009).
19. Group BDW. Biomarkers and surrogate end points:preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
20. Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad. Med. J. 85(1008), 538-545 (2009).
21. Schwarz E, Bahn S. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br. J. Pharmacol. 153(Suppl. 1), S133-S136 (2008).
22. Frey BN, Andreazza AC, Houenou J et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry 47(4), 321-332 (2013).
23. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37(1), 13-25 (2010).
24. Kastin AJ, Akerstrom V, Pan W. Neuregulin-1-β1 enters brain and spinal cord by receptor-mediated transport. J. Neurochem. 88(4), 965-970 (2004).
25. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37(12), 1553-1561 (1998).
26. Pillai A, Kale A, Joshi S et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int. J. Neuropsychopharmacol. 13(4), 535-539 (2010).
27. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin. Sci. 110(2), 167-173 (2006).
28. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int. J. Neuropsychopharmacol. 12(4), 441-445 (2009).
29. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol. Psychiatry 62(5), 530-535 (2007).
30. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35(12), 2378-2391 (2010).
31. Cunha AB, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398(3), 215-219 (2006).
32. Goldstein BI, Collinger KA, Lotrich F et al. Preliminary findings regarding proinflammatory markers and brainderived neurotrophic factor among adolescents with bipolar spectrum disorders. J. Child Adolesc. Psychopharmacol. 21(5), 479-484 (2011).
33. Machado-Vieira R, Andreazza AC, Viale CI et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421(1), 33-36 (2007).
34. de Oliveira GS, Ceresér KM, Fernandes BS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J. Psychiatr. Res. 43(14), 1171-1174 (2009).
35. Pandey GN, Rizavi HS, Dwivedi Y, Pavuluri MN. Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. J. Am. Acad. Child Adolesc. Psychiatry 47(9), 1077-1085 (2008).
36. Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 10(1), 95-100 (2008).
37. Barbosa IG, Rocha NP, Miranda AS et al. Increased BDNF levels in long-term bipolar disorder patients. Rev. Bras. Psiquiatr. 35(1), 67-69 (2013).
38. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 11(6), 663-671 (2009).
39. Huang TL, Hung YY, Lee CT, Chen RF. Serum protein levels of brain-derived neurotrophic factor and tropomyosinrelated kinase B in bipolar disorder: effects of mood stabilizers. Neuropsychobiology 65(2), 65-69 (2012).
40. Fernandes BS, Gama CS, Ceresér KM et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J. Psychiatr. Res. 45(8), 995-1004 (2011).
41. Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatry 65(6), 489-494 (2009).
42. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 12(4), 447-458 (2009).
43. Yatham LN, Kapczinski F, Andreazza AC, Trevor Young L, Lam RW, Kauer- Sant'anna M. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. Int. J. Neuropsychopharmacol. 12(1), 137-139 (2009).
44. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(8), 1366-1371 (2009).
45. Tramontina JF, Andreazza AC, Kauer- Sant'anna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 452(2), 111-113 (2009).
46. Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int. J. Neuropsychopharmacol. 13(5), 617-622 (2010).
47. de Sousa RT, van de Bilt MT, Diniz BS et al. Lithium increases plasma brainderived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci. Lett. 494(1), 54-56 (2011).
48. Walz JC, Andreazza AC, Frey BN et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci. Lett. 415(1), 87-89 (2007).
49. Fernandes BS, Gama CS, Walz JC et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J. Psychiatr. Res. 44(9), 561-565 (2010).
50. Walz JC, Magalhães PV, Giglio LM et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J. Psychiatr. Res. 43(7), 721-723 (2009).
51. Barbosa IG, Huguet RB, Sousa LP et al. Circulating levels of GDNF in bipolar disorder. Neurosci. Lett. 502(2), 103-106 (2011).
52. Rosa AR, Frey BN, Andreazza AC et al. Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci. Lett. 407(2), 146-150 (2006).
53. Zhang X, Zhang Z, Sha W et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in bipolar patients. J. Affect. Disord. 126(1-2), 326-329 (2010).
54. Takebayashi M, Hisaoka K, Nishida A et al. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int. J. Neuropsychopharmacol. 9(5), 607-612 (2006).
55. Lundborg C, Hahn-Zoric M, Biber B, Hansson E. Glial cell line-derived neurotrophic factor is increased in cerebrospinal fluid but decreased in blood during long-term pain. J. Neuroimmunol. 220(1-2), 108-113 (2010).
56. Leboyer M, Soreca I, Scott J et al. Can bipolar disorder be viewed as a multisystem inflammatory disease? J. Affect. Disord. 141(1), 1-10 (2012).
57. Barbosa IG, Rocha NP, Bauer ME et al. Chemokines in bipolar disorder: trait or state? Eur. Arch. Psychiatry Clin. Neurosci. 263(2), 159-165 (2013).
58. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 23(2), 87-94 (2008).
59. Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci. Lett. 499(3), 149-153 (2011).
60. Brietzke E, Stertz L, Fernandes BS et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 116(3), 214-217 (2009).
61. Ortiz-Domínguez A, Hernández ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 9(6), 596-602 (2007).
62. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104(1-3), 91-95 (2007).
63. Munkholm K, Vinberg M, Berk M, Kessing LV. State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord. 14(7), 684-696 (2012).
64. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry doi:10.1016/j.biopsych. 2013.01.007 (2013) (Epub ahead of print).
65. Padmos RC, Hillegers MH, Knijff EM et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65(4), 395-407 (2008).
66. Padmos RC, Van Baal GC, Vonk R et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch. Gen. Psychiatry 66(9), 957-965 (2009).
67. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol. 13(10), 1369-1381 (2010).
68. Herberth M, Koethe D, Levin Y et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 11(1), 94-105 (2011).
69. Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr. Bull. 35(6), 1045-1056 (2009).
70. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70(8), 1078-1090 (2009).
71. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr. Psychiatry Rep. 11(6), 475-480 (2009).
72. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J. Affect. Disord. 126(3), 366-387 (2010).
73. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann. Clin. Psychiatry 23(1), 40-47 (2011).
74. Berk M, Malhi GS, Hallam K et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J. Affect. Disord. 114(1-3), 1-13 (2009).
75. Hamdani N, Tamouza R, Leboyer M. Immuno- inflammatory markers of bipolar disorder: a review of evidence. Front. Biosci. (Elite Ed.) 4, 2170-2182 (2012).
76. Stertz L, Magalhães PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr. Opin. Psychiatry 26(1), 19-26 (2013).
77. Knijff EM, Breunis MN, Kupka RW et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 9(7), 743-753 (2007).
78. Guloksuz S, Altinbas K, Aktas Cetin E et al. Evidence for an association between tumor necrosis factor-α levels and lithium response. J. Affect. Disord. 143(1-3), 148-152 (2012).
79. Andreazza AC, Kauer-Sant'anna M, Frey BN et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord. 111(2-3), 135-144 (2008).
80. Dean OM, van den Buuse M, Bush AI et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr. Med. Chem. 16(23), 2965-2976 (2009).
81. Zhang XY, Yao JK. Oxidative stress and therapeutic implications in psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry doi:10.1016/j.pnpbp. 2013.03.003 (2013) (Epub ahead of print).
82. Halliwell B, Gutteridg J. Radicals in Biology and Medicine (4th Edition). Oxford University Press, NY, USA (2007).
83. Olmez I, Ozyurt H. Reactive oxygen species and ischemic cerebrovascular disease. Neurochem. Int. 60(2), 208-212 (2012).
84. Khairova R, Pawar R, Salvadore G et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol. Med. Rep. 5(3), 680-682 (2012).
85. Halliwell B. Free radicals and antioxidants - quo vadis? Trends Pharmacol. Sci. 32(3), 125-130 (2011).
86. Wood SJ, Berger GE, Wellard RM et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol. Dis. 33(3), 354-357 (2009).
87. Dröse S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 748, 145-169 (2012).
88. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry 67(4), 360-368 (2010).
89. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 14(1), 123-130 (2011).
90. Andreazza AC, Cassini C, Rosa AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 41(6), 523-529 (2007).
91. Kunz M, Gama CS, Andreazza AC et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(7), 1677-1681 (2008).
92. Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J. Affect. Disord. 107(1-3), 89-94 (2008).
93. Gergerlioglu HS, Savas HA, Bulbul F, Selek S, Uz E, Yumru M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(3), 697-702 (2007).
94. Ranjekar PK, Hinge A, Hegde MV et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121(2), 109-122 (2003).
95. Raffa M, Barhoumi S, Atig F, Fendri C, Kerkeni A, Mechri A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 39(2), 371-375 (2012).
96. Andreazza AC, Frey BN, Erdtmann B et al. DNA damage in bipolar disorder. Psychiatry Res. 153(1), 27-32 (2007).
97. Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 16(2-3), 183-193 (2008).
98. Berk M, Dean OM, Cotton SM et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med. 10, 91 (2012).
99. Berk M, Copolov DL, Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol. Psychiatry 64(6), 468-475 (2008).
100. Magalhães PV, Dean OM, Bush AI et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J. Affect. Disord. 129(1-3), 317-320 (2011).
101. Magalhães PV, Dean OM, Bush AI et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev. Bras. Psiquiatr. 33(4), 374-378 (2011).
102. Manji H, Kato T, Di Prospero NA et al. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 13(5), 293-307 (2012).
103. Cataldo AM, McPhie DL, Lange NT et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am. J. Pathol. 177(2), 575-585 (2010).
104. Regenold WT, Pratt M, Nekkalapu S, Shapiro PS, Kristian T, Fiskum G. Mitochondrial detachment of hexokinase 1 in mood and psychotic disorders: implications for brain energy metabolism and neurotrophic signaling. J. Psychiatr. Res. 46(1), 95-104 (2012).
105. Valvassori SS, Rezin GT, Ferreira CL et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J. Psychiatr. Res. 44(14), 903-909 (2010).
106. Bachmann RF, Wang Y, Yuan P et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int. J. Neuropsychopharmacol. 12(6), 805-822 (2009).
107. Maurer IC, Schippel P, Volz HP. Lithiuminduced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 11(5), 515-522 (2009).
108. Post RM, Fleming J, Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J. Psychiatr. Res. 46(5), 561-573 (2012).
109. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr. Clin. North Am. 28(2), 469-480 (2005).
110. Tatro ET, Everall IP, Kaul M, Achim CL. Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain Res. 1286, 1-12 (2009).
111. Cervantes P, Gelber S, Kin FN, Nair VN, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J. Psychiatry Neurosci. 26(5), 411-416 (2001).
112. Du J, Wang Y, Hunter R et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc. Natl Acad. Sci. USA 106(9), 3543-3548 (2009).
113. Gong Y, Chai Y, Ding JH, Sun XL, Hu G. Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain. Neurosci. Lett. 488(1), 76-80 (2011).
114. Sorrells SF, Caso JR, Munhoz CD, Sapolsky RM. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 64(1), 33-39 (2009).
115. Yamamoto BK, Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol. 3(4), 203-217 (2008).
116. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol. 14(1), 20-28 (2004).
117. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 334(6059), 1081-1086 (2011).
118. Kimata Y, Kohno K. Endoplasmic reticulum stress-sensing mechanisms in yeast and mammalian cells. Curr. Opin. Cell Biol. 23(2), 135-142 (2011).
119. So J, Warsh JJ, Li PP. Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder. Biol. Psychiatry 62(2), 141-147 (2007).
120. Hayashi A, Kasahara T, Kametani M, Toyota T, Yoshikawa T, Kato T. Aberrant endoplasmic reticulum stress response in lymphoblastoid cells from patients with bipolar disorder. Int. J. Neuropsychopharmacol. 12(1), 33-43 (2009).
121. Kakiuchi C, Ishigaki S, Oslowski CM, Fonseca SG, Kato T, Urano F. Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94. PLoS ONE 4(1), e4134 (2009).
122. Kim B, Kim CY, Lee MJ, Joo YH. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 168(3), 209-212 (2009).
123. Zhang Z, Tong N, Gong Y et al. Valproate protects the retina from endoplasmic reticulum stress-induced apoptosis after ischemia-reperfusion injury. Neurosci. Lett. 504(2), 88-92 (2011).
124. Pfaffenseller B, Aguiar BW, Fries GR. Impaired endoplasmic reticulum stress response in lymphocytes from patients with bipolar diosrder. In: 10th International Congress on Cell Biology and the 16th Meeting of the Brazilian Society for Cell Biology. Rio de Janeiro, Brazil, 25-28 July 2012. 125 Vandenberghe W, Nicoll RA, Bredt DS. Interaction with the unfolded protein response reveals a role for stargazin in biosynthetic AMPA receptor transport. J. Neurosci. 25(5), 1095-1102 (2005).
125. Verkhratsky A. The endoplasmic reticulum and neuronal calcium signalling. Cell Calcium 32(5-6), 393-404 (2002).
126. Weng WC, Lee WT, Hsu WM, Chang BE, Lee H. Role of glucose-regulated Protein 78 in embryonic development and neurological disorders. J. Formos. Med. Assoc. 110(7), 428-437 (2011).
127. Giorgi C, De Stefani D, Bononi A, Rizzuto R, Pinton P. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int. J. Biochem. Cell Biol. 41(10), 1817-1827 (2009).
128. Wang X, Eno CO, Altman BJ et al. ER stress modulates cellular metabolism. Biochem. J. 435(1), 285-296 (2011).
129. Uemura T, Green M, Corson TW, Perova T, Li PP, Warsh JJ. Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Bipolar Disord. 13(1), 41-51 (2011).
130. Csordás G, Hajnóczky G. SR/ER-mitochondrial local communication: calcium and ROS. Biochim. Biophys. Acta 1787(11), 1352-1362 (2009).
131. Chen G, Fan Z, Wang X et al. Brainderived neurotrophic factor suppresses tunicamycin-induced upregulation of CHOP in neurons. J. Neurosci. Res. 85(8), 1674-1684 (2007).
132. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog. Neurobiol. 100, 15-29 (2013).
133. Malhotra JD, Miao H, Zhang K et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc. Natl Acad. Sci. USA 105(47), 18525-18530 (2008).
134. Adolph TE, Niederreiter L, Blumberg RS, Kaser A. Endoplasmic reticulum stress and inflammation. Dig. Dis. 30(4), 341-346 (2012).
135. Parpura V, Heneka MT, Montana V et al. Glial cells in (patho)physiology. J. Neurochem. 121(1), 4-27 (2012).
136. Altshuler LL, Abulseoud OA, Foland-Ross L et al. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord. 12(5), 541-549 (2010).
137. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch. Gen. Psychiatry 67(2), 155-166 (2010).
138. Silvestroff L, Franco PG, Pasquini JM. ApoTransferrin: dual role on adult subventricular zone-derived neurospheres. PLoS ONE 7(3), e33937 (2012).
139. Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr. Res. 112(1-3), 54-64 (2009).
140. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 15(4), 384-392 (2010).
141. Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 33(2), 191-206 (2012).
142. Taveggia C, Thaker P, Petrylak A et al. Type III neuregulin-1 promotes oligodendrocyte myelination. Glia 56(3), 284-293 (2008).
143. Ongür D, Jensen JE, Prescot AP et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol. Psychiatry 64(8), 718-726 (2008).
144. Fries GR, Kapczinski F. N-acetylcysteine as a mitochondrial enhancer: a new class of psychoactive drugs? Rev. Bras. Psiquiatr. 33(4), 321-322 (2011).
145. Ferreira AP, Pasin JS, Saraiva AL et al. N-acetylcysteine prevents baker's-yeast- induced inflammation and fever. Inflamm. Res. 61(2), 103-112 (2012).
146. Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J. Affect. Disord. 126(3), 458-462 (2010).
147. Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr. Mol. Pharmacol. 2(2), 207-214 (2009).
148. Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol. Psychiatry 16(4), 419-428 (2011).
149. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 26(5), 391-401 (2012).
150. Hailer NP. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog. Neurobiol. 84(3), 211-233 (2008).
151. Pae CU, Marks DM, Han C, Patkar AA. Does minocycline have antidepressant effect? Biomed. Pharmacother. 62(5), 308-311 (2008).
152. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-ofconcept, randomised, double-blind, placebo-controlled, 2 × 2 clinical trial. BMJ Open 2(1), e000643 (2012).
153. Wu A, Ying Z, Gomez-Pinilla F. Dietary γ-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma 21(10), 1457-1467 (2004).
154. Sarris J, Mischoulon D, Schweitzer I. γ-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J. Clin. Psychiatry 73(1), 81-86 (2012).
155. Balanzα-Martínez V, Fries GR, Colpo GD et al. Therapeutic use of γ-3 fatty acids in bipolar disorder. Expert Rev. Neurother. 11(7), 1029-1047 (2011).
156. Soeiro-de-Souza MG, Dias VV, Figueira ML et al. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr. Scand. 126(5), 332-341 (2012).
157. Hosseinkhani H, Hosseinkhani M. Biodegradable polymer-metal complexes for gene and drug delivery. Curr. Drug Saf. 4(1), 79-83 (2009).
158. Mohtaram NK, Montgomery A, Willerth SM. Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors. Biomed. Mater. 8(2), 022001 (2013).
159. Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol. Rev. 65(1), 105-142 (2013).
160. Gigante AD, Young LT, Yatham LN et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int. J. Neuropsychopharmacol. 14(8), 1075-1089 (2011).
161. Chaudhary M, Rao PV. Brain oxidative stress after dermal and subcutaneous exposure of T-2 toxin in mice. Food Chem. Toxicol. 48(12), 3436-3442 (2010).
162. de Gonzalo-Calvo D, Neitzert K, Fernαndez M et al. Differential inflammatory responses in aging and disease: TNF-α and IL-6 as possible biomarkers. Free Radic. Biol. Med. 49(5), 733-737 (2010).
163. Kapczinski F, Frey BN, Andreazza AC, Kauer-Sant'Anna M, Cunha AB, Post RM. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev. Bras. Psiquiatr. 30(3), 243-245 (2008).
164. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 420(1), 45-48 (2007).
165. Hope S, Dieset I, Agartz I et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res. 45(12), 1608-1616 (2011).
166. Maes M, Delange J, Ranjan R et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 66(1), 1-11 (1997).
167. Kim YK, Suh IB, Kim H et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 7(10), 1107-1114 (2002).
168. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther. 8(12), 1955-1962 (2008).